We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+11.31%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$826M
AUM Growth
-$75.1M
Cap. Flow
-$116M
Cap. Flow %
-14%
Top 10 Hldgs %
53.79%
Holding
72
New
9
Increased
9
Reduced
17
Closed
17

Top Buys

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$14.5M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.93M
3
ENDP
Endo International plc
ENDP
+$4.02M
4
DXCM icon
DexCom
DXCM
+$3.85M
5
JUNO
Juno Therapeutics, Inc.
JUNO
+$3.77M

Top Sells

Rank Stock Value
1
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$69.4M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$23.5M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$18.6M
4
GNMX
Aevi Genomic Medicine Inc
GNMX
+$15.2M
5
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 77.21%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXTR
51
DELISTED
Dextera Surgical Inc.
DXTR
$635K 0.08%
599,440
-236,927
-28% -$304K
SSKN
52
DELISTED
Strata Skin Sciences
SSKN
$582K 0.07%
19,228
– –
ATEC icon
53
Alphatec Holdings
ATEC
$1.27B
$527K 0.06%
+226,006
New +$722K
GKOS icon
54
Glaukos
GKOS
$9.02B
– –
-141,300
Closed -$4.85M
MDT icon
55
Medtronic
MDT
$107B
– –
-75,000
Closed -$5.34M
PCRX icon
56
CALL
Pacira BioSciences
PCRX
$1.02B
– –
-150,000
Closed -$4.84M
PCRX icon
57
Pacira BioSciences
PCRX
$1.02B
– –
-150,680
Closed -$4.87M
PTN
58
Palatin Technologies
PTN
$13.7M
– –
-3,077
Closed -$1.94M
RDHL
59
Redhill Biopharma
RDHL
$3.85M
– –
-252
Closed -$2.63M
TENX icon
60
Tenax Therapeutics
TENX
$385M
– –
-62
Closed -$3.84M
TEVA icon
61
Teva Pharmaceuticals
TEVA
$35.9B
– –
-647,500
Closed -$23.5M
TRUP icon
62
Trupanion
TRUP
$1.05B
– –
-67,065
Closed -$1.04M
ZBH icon
63
Zimmer Biomet
ZBH
$17.7B
– –
-86,005
Closed -$8.62M
NVRO
64
DELISTED
NEVRO CORP.
NVRO
– –
-43,281
Closed -$3.15M
ACOR
65
DELISTED
Acorda Therapeutics
ACOR
– –
-5,368
Closed -$12.1M
GNMX
66
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-3,370,306
Closed -$15.2M
EGLT
67
DELISTED
Egalet Corporation
EGLT
– –
-556,233
Closed -$4.25M
NVDQ
68
DELISTED
Novadaq Technologies Inc.
NVDQ
– –
-407,188
Closed -$2.89M
ZGNX
69
DELISTED
Zogenix, Inc.
ZGNX
– –
-766,412
Closed -$9.31M
DSCI
70
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
– –
-2,562,104
Closed -$13.3M
1 2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Broadfin Capital held 72 positions worth $826M, down 8.3% from $901M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Broadfin Capital withdrew a net $116M in Q1 2017, closing 17 positions and reducing 17 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $23.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 89% a quarter earlier, followed by Financials.

Against the trend, Broadfin Capital opened a new position in DexCom worth $4.18M.

  • Broadfin Capital's largest Q1 2017 buy was DexCom: 197,200 shares worth $4.18M.
  • Broadfin Capital added most to Heron Therapeutics in Q1 2017, an estimated $14.5M increase.
  • Broadfin Capital's biggest Q1 2017 reduction was Progenics Pharmaceuticals Inc, cutting an estimated $69.4M.
  • Broadfin Capital fully exited Teva Pharmaceuticals in Q1 2017, selling an estimated $23.5M.
  • Broadfin Capital's ten largest holdings make up 54% of its $826M portfolio in Q1 2017.
  • Broadfin Capital opened 9 new positions and closed 17 in Q1 2017.
  • Broadfin Capital's portfolio value fell 8.3% quarter-over-quarter to $826M.

Based on Broadfin Capital's 13F filing for Q1 2017, filed 15 May 2017.